Latest Events: Community Investment Call from 7/30/19 Listen Here

Investor Relations

Upcoming Event

CDRH Face-to-Face Meeting

Aug 28, 2019

Latest Financial Results

FY 2019

Fiscal Year Ended May 31, 2019

Latest Annual Filing

For Year Ending May 31, 2019

Email Alerts

Stay informed and receive company updates straight to your inbox

Sign up today

Company Overview

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells.  The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as graft-vs-host disease (GvHD) and NASH.

Investor Contact Information

Company

CytoDyn Inc.
1111 Main Street
Suite 660
Vancouver, WA 98660
T: 360-980-8524
F: 360-980-8549
info@cytodyn.com

Investor Relations

Marek Ciszewski, J.D.
T: 630-707-8585
mciszewski@cytodyn.com

Transfer Agent

Computershare
c/o Shareholder Services
P.O. Box 505002
Louisville, KY 40233-5002
T: 800-962-4284